Dashboard
Manage Tickers

SPRYARS Pharmaceuticals, Inc.

Nasdaq ars-pharma.com


$ 12.86 $ -0.12 (-0.89 %)    

Tuesday, 17-Sep-2024 14:19:06 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 472.83 $ -3.14 (-0.66 %)
DIA $ 417.40 $ -0.58 (-0.14 %)
SPY $ 562.59 $ -2.54 (-0.45 %)
TLT $ 100.88 $ -0.51 (-0.5 %)
GLD $ 237.49 $ -0.49 (-0.21 %)
$ 12.95
$ 12.98
$ 12.85 x 223
-- x --
$ 12.65 - $ 13.31
$ 2.55 - $ 16.50
874,400
na
1.26B
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-21-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-23-2023 12-31-2022 10-K
8 11-02-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-31-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 03-29-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-ars-pharmaceuticals-maintains-30-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/16/2024 17:02:42

Cantor Fitzgerald analyst Josh Schimmer reiterates ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and maintains $30 pri...

ars-pharmaceuticals-reports-submission-of-snda-for-neffy-1-mg-for-treatment-of-type-i-allergic-reactions-including-anaphylaxis-in-children-who-weigh-15-to-30-kg
ARS Pharmaceuticals Reports Submission Of ...
09/09/2024 20:49:24

analyst-ratings-for-ars-pharmaceuticals
Analyst Ratings For ARS Pharmaceuticals
09/09/2024 18:00:19

cantor-fitzgerald-reiterates-overweight-on-ars-pharmaceuticals-maintains-30-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 16:15:18

Cantor Fitzgerald analyst Josh Schimmer reiterates ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and maintains $30 pri...

ars-pharmaceuticals-launches-pre-ordering-services-for-neffy-to-help-patients-access-the-treatment-for-type-i-allergic-reactions-including-anaphylaxis
ARS Pharmaceuticals Launches Pre-Ordering ...
09/04/2024 12:19:39

Patients can request a prescription from their existing healthcare provider, or meet with a physician virtually, to request a p...

newly-approved-ars-pharmaceuticals-needle-free-neffy-offers-convenience-over-epipen-for-allergic-reaction-but-real-world-efficacy-questioned-updated
Newly Approved ARS Pharmaceuticals' Needle...
08/27/2024 14:08:56

Neffy, a nasal spray alternative to EpiPen, offers convenience and longer shelf life but faces skepticism from allergists due t...

Core News & Articles
ARS Pharmaceuticals' EURneffy Adrenaline N...
08/26/2024 13:30:33

Marking First New Delivery Method In EU In Over 30 Years

ars-pharmaceuticals-neffy-uniquely-positioned-with-potential-to-change-allergy-treatment-paradigm-for-first-time-in-40-years-analyst
ARS Pharmaceuticals 'Neffy Uniquely Positi...
08/20/2024 16:21:45

"FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative...

fabrinet-posts-strong-earnings-joins-amer-sports-hawaiian-holdings-and-other-big-stocks-moving-higher-on-tuesday
Fabrinet Posts Strong Earnings, Joins Amer...
08/20/2024 14:07:32

cantor-fitzgerald-initiates-coverage-on-ars-pharmaceuticals-with-overweight-rating-announces-price-target-of-30
Cantor Fitzgerald Initiates Coverage On AR...
08/20/2024 09:43:09

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight rating and...

looking-into-ars-pharmaceuticalss-recent-short-interest
Looking Into ARS Pharmaceuticals's Recent ...
08/19/2024 17:30:19

loar-holdings-posts-upbeat-results-joins-nvidia-clean-energy-fuels-penumbra-and-other-big-stocks-moving-higher-on-tuesday
Loar Holdings Posts Upbeat Results, Joins ...
08/13/2024 15:44:24

raymond-james-upgrades-ars-pharmaceuticals-to-strong-buy-raises-price-target-to-22
Raymond James Upgrades ARS Pharmaceuticals...
08/13/2024 09:35:22

Raymond James analyst Ryan Deschner upgrades ARS Pharmaceuticals (NASDAQ:SPRY) from Outperform to Strong Buy and raises the ...

fda-approves-ars-pharmas-once-rejected-neffy-nasal-spray-alternative-to-epipen-for-emergency-allergy-treatment
FDA Approves ARS Pharma's Once Rejected Ne...
08/09/2024 17:34:40

FDA approves ARS Pharmaceuticals' Neffy, the first nasal spray for treating severe allergic reactions and anaphylaxis. This...

ars-pharmaceuticals-says-for-eligible-patients-without-insurance-coverage-co-will-offer-a-cash-price-of-199-for-two-doses-of-neffy-via-blinkrx
ARS Pharmaceuticals Says For Eligible Pati...
08/09/2024 16:54:12

fda-approves-first-nasal-spray-for-treatment-of-anaphylaxis-approved-neffy-epinephrine-nasal-spray-for-emergency-treatment-of-allergic-reactions-type-i
FDA Approves First Nasal Spray For Treatme...
08/09/2024 15:25:31

- Reuters

ars-pharmaceuticals-q2-eps-013-misses-012-estimate-sales-50000k-miss-100m-estimate
ARS Pharmaceuticals Q2 EPS $(0.13) Misses ...
08/06/2024 20:28:56

ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of...

raymond-james-initiates-coverage-on-ars-pharmaceuticals-with-outperform-rating-announces-price-target-of-18
Raymond James Initiates Coverage On ARS Ph...
07/25/2024 16:59:24

Raymond James analyst Ryan Deschner initiates coverage on ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform rating and ann...

ars-pharmaceuticals-says-chmp-of-european-medicines-agency-adopted-positive-opinion-on-application-for-marketing-authorization-for-eurneffy-adrenaline-nasal-spray
ARS Pharmaceuticals Says CHMP Of European ...
06/28/2024 10:31:51

The CHMP recommended related market authorization in the European Union (EU) for the emergency treatment of allergic reactions ...

ars-pharmaceuticals-q1-2024-gaap-eps-011-inline
ARS Pharmaceuticals Q1 2024 GAAP EPS $(0.1...
05/09/2024 21:29:25

ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION